Specific antibody to Cryptococcus neoformans glucurunoxylomannan antagonizes antifungal drug action against cryptococcal biofilms in vitro

Journal of Infectious Diseases

Volumn 194, Issue 2, 2006, Pages 261-266

  Martinez, Luis R ^a   Christaki, Eirini ^a   Casadevall, Arturo ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; GLUCURONOXYLOMANNAN; POLYSACCHARIDE;

ANIMAL CELL; ANTIBODY SPECIFICITY; ANTIFUNGAL ACTIVITY; ANTIGEN PRESENTATION; ARTICLE; BIOFILM; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG RESISTANCE; IMMUNE RESPONSE; IN VITRO STUDY; NONHUMAN; PHAGOCYTOSIS; PLANKTON; PRIORITY JOURNAL;

AMPHOTERICIN B; ANTIBODIES, FUNGAL; ANTIFUNGAL AGENTS; BIOFILMS; CRYPTOCOCCUS NEOFORMANS; MANNANS; PEPTIDES, CYCLIC;

EID: 33746120262     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/504722     Document Type: Article

References (15)

1. Casadevall A, Perfect JR. Cryptococcus neoformans. Washington DC: ASM Press, 1998.
2. Vecchiarelli A. Immunoregulation by capsular components of Cryptococcus neoformans. Med Mycol 2000; 38:407-17.
3. Martinez LR, Casadevall A. Specific antibody can prevent fungal biofilm formation and this effect correlates with protective efficacy. Infect Immun 2005; 73:6350-62.
4. Walsh TJ, Schlegel R, Moody MM, Costerton JW, Salcman M. Ventriculoatrial shunt infection due to Cryptococcus neoformans: an ultrastructural and quantitative microbiological study. Neurosurgery 1986; 18:373-5.
5. Banerjee U, Gupta K, Venugopal P. A case of prosthetic valve endocarditis caused by Cryptococcus neoformans var. neoformans. J Med Vet Mycol 1997; 35:139-41.
6. Braun DK, Janssen DA, Marcus JR, Kauffman CA. Cryptococcal infection of a prosthetic dialysis fistula. Am J Kidney Dis 1994; 24: 864-7.
7. Penk A, Pittrow L. Role of fluconazole in the long-term suppressive therapy of fungal infections in patients with artificial implants. Mycoses 1999; 42(Suppl 2):91-6.
8. Martinez LR, Casadevall A. Susceptibility of Cryptococcus neoformans biofilms to antifungal agents in vitro. Antimicrob Agents Chemother 2006; 50:1021-33.
9. Larsen RA, Pappas PG, Perfect I, et al. Phase I evaluation of the safety and pharmacokinetics of murine-derived anticryptococcal antibody 18B7 in subjects with treated cryptococcal meningitis. Antimicrob Agents Chemother 2005; 49:952-8.
10. Matthews RC, Burnie JP. Human recombinant antibody to HSP90: a natural partner in combination therapy. Curr Mol Med 2005; 5: 403-11.
11. Mukherjee J, Zuckier LS, Scharff MD, Casadevall A. Therapeutic efficacy of monoclonal antibodies to Cryptococcus neoformans glucorunoxylomannan alone and in combination with amphotericin B. Antimicrob Agents Chemother 1994; 38:580-7.
12. Dromer F, Charreire J. Improved amphotericin B activity by a monoclonal anti-Cryptococcus neoformans antibody: study during murine cryptococcosis and mechanisms of action. J Infect Dis 1991; 163:1114-20.
13. Matthews RC, Rigg G, Hodgetts S, et al. Preclinical assessment of the efficacy of Mycograb, a human recombinant antibody against fungal HSP90. Antimicrob Agents Chemother 2003; 47:2208-16.
14. Nooney L, Matthews RC, Burnie JP. Evaluation of Mycograb, amphotericin B, caspofungin, and fluconazole in combination against Cryptococcus neoformans by checkerboard and time-kill methodologies. Diagn Microbiol Infect Dis 2005; 51:19-29.
15. Meshulam T, Levitz SM, Christin L, Diamond RD. A simplified new assay for assessment of fungal cell damage with the tetrazolium dye, (2,3)-bis-(2- methoxy-4-nitro-5-sulphenyl)-(2H)-tetrazolium-5-carboxanilide (XTT). J Infect Dis 1995; 172:1153-6.